The following is a summary of "Sex differences in outcomes in patients with acute myocardial infarction," published in the ...

A potential strategy introduces an entirely new type of therapy capable of addressing previously ‘undruggable’ targets within ...

Patients hospitalized for heart failure who have cannabis use disorder (CUD) are significantly more likely to experience ...

New clinical results from multiple studies show coronary heart disease death associated with tobacco use is anticipated to rise up to 40% in the next five years and people with cannabis use disorder ...

Zydus Lifesciences Ltd. has secured final USFDA approval to manufacture generic Niacin extended-release tablets in 500 mg, ...

For patients with asymptomatic or symptomatic carotid stenosis of 50 percent or greater with a low or intermediate predicted ...

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration to manufacture ...

Alembic Pharmaceuticals has received USFDA approval to market generic Ticagrelor Tablets, a medication for preventing heart ...

In a recent study, one-year MACE incidences were 1.79, 2.58, and 4.03 per 100 patient-years for early, late, and no ezetimibe added to statins.

Vadodara: Alembic Pharmaceuticals Limited has announced that the US Food & Drug Administration (USFDA) has given final ...

Inflammation is likely a key player in atherosclerosis and related cardiovascular events, but questions remain about its role ...